Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Allergan has announced that it intends to file a new drug application by end of the third quarter of 2008 with the FDA for bimatoprost, a synthetic prostaglandin analog, as a treatment to stimulate eyelash growth.
Subscribe to our email newsletter
Allergan has completed its clinical trial program demonstrating that its patented formulation of bimatoprost, when applied directly to the base of the eyelashes, results in significant eyelash growth.
The company has said that if approved by the FDA, Allergan’s bimatoprost product for eyelash growth will be available by prescription only to consumers in the US.
Scott Whitcup, executive vice president of R&D at Allergan, said: “Our exploration of bimatoprost as an eyelash growth enhancer reflects our continuing commitment to offer innovative medical aesthetic treatments that are science-based, with the clinically proven safety and efficacy that consumers have come to trust Allergan to provide.”